GENETWORx Labs Launches New Breakthrough Diagnostic Flu A-B/COVID-19/RSV Combination Test
By LabMedica International staff writers Posted on 02 Dec 2020 |
Image: GENETWORx Labs Launches New Breakthrough Diagnostic Flu A-B/COVID-19/RSV Combination Test (Photo courtesy of TCA/GENETWORx Labs)
TCA/GENETWORx Labs (Glen Allen, VA, USA) has unveiled a new breakthrough diagnostic Flu A-B/COVID-19/RSV combination test that provides patients with early detection of all three separate respiratory viruses with just one test sample.
With people inside homes, businesses, and schools during the cold weather months where there is less ventilation, the COVID-19 virus coupled with influenza and RSV (Respiratory Syncytial Virus) pose a formidable and unprecedented infectious disease threat, particularly since these viruses share similar symptoms. To help battle this triple threat, the new TCA/GENETWORx Combo PCR test provides patients the ability to detect strands of influenza A and B, RSV, and COVID-19 all from a single sample. The molecular diagnostic PCR test detects two types of influenza viruses - influenza A and B - and differentiates them from RSV, and SARS-CoV-2, the virus that causes COVID-19. The Flu A-B/COVID Combo Test provided by GENETWORx has a 98% accuracy rate for influenza, 99% for COVID-19, and 96% for RSV.
The capability to test for influenza A/B, RSV, and COVID-19 from a single mid-turbinate or nasopharyngeal swab sample means less discomfort for patients when compared with collecting a separate sample for each test. Testing a single sample for several pathogens uses fewer resources and takes less time when compared with running several individual tests on multiple samples to detect different pathogens.
An approval date for a COVID-19 vaccine is still yet to be determined and the flu vaccine is dependent on which strain of influenza is circulating each year. There is currently no vaccine for RSV. Even with the correct strain, the flu vaccine is not 100% reliable. With all the unknowns and risks associated with this upcoming flu and RSV season, the new TCA/GENETWORx test is an important advancement in diagnostic medicine during the pandemic.
"With this new combination test, healthcare providers can provide an accurate diagnosis to patients and treat them with the appropriate measures. Patients then can observe appropriate quarantine measures to stop the spread," said William Miller, CEO of GENETWORx Labs. "Having a combination test that detects three different viruses is a healthcare breakthrough for both providers and patients and will save lives. The Combo test is also easier on patients since only one sample is needed for three answers."
Related Links:
TCA/GENETWORx Labs
With people inside homes, businesses, and schools during the cold weather months where there is less ventilation, the COVID-19 virus coupled with influenza and RSV (Respiratory Syncytial Virus) pose a formidable and unprecedented infectious disease threat, particularly since these viruses share similar symptoms. To help battle this triple threat, the new TCA/GENETWORx Combo PCR test provides patients the ability to detect strands of influenza A and B, RSV, and COVID-19 all from a single sample. The molecular diagnostic PCR test detects two types of influenza viruses - influenza A and B - and differentiates them from RSV, and SARS-CoV-2, the virus that causes COVID-19. The Flu A-B/COVID Combo Test provided by GENETWORx has a 98% accuracy rate for influenza, 99% for COVID-19, and 96% for RSV.
The capability to test for influenza A/B, RSV, and COVID-19 from a single mid-turbinate or nasopharyngeal swab sample means less discomfort for patients when compared with collecting a separate sample for each test. Testing a single sample for several pathogens uses fewer resources and takes less time when compared with running several individual tests on multiple samples to detect different pathogens.
An approval date for a COVID-19 vaccine is still yet to be determined and the flu vaccine is dependent on which strain of influenza is circulating each year. There is currently no vaccine for RSV. Even with the correct strain, the flu vaccine is not 100% reliable. With all the unknowns and risks associated with this upcoming flu and RSV season, the new TCA/GENETWORx test is an important advancement in diagnostic medicine during the pandemic.
"With this new combination test, healthcare providers can provide an accurate diagnosis to patients and treat them with the appropriate measures. Patients then can observe appropriate quarantine measures to stop the spread," said William Miller, CEO of GENETWORx Labs. "Having a combination test that detects three different viruses is a healthcare breakthrough for both providers and patients and will save lives. The Combo test is also easier on patients since only one sample is needed for three answers."
Related Links:
TCA/GENETWORx Labs
Latest COVID-19 News
- New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases
- Long COVID Etiologies Found in Acute Infection Blood Samples
- Novel Device Detects COVID-19 Antibodies in Five Minutes
- CRISPR-Powered COVID-19 Test Detects SARS-CoV-2 in 30 Minutes Using Gene Scissors
- Gut Microbiome Dysbiosis Linked to COVID-19
- Novel SARS CoV-2 Rapid Antigen Test Validated for Diagnostic Accuracy
- New COVID + Flu + R.S.V. Test to Help Prepare for `Tripledemic`
- AI Takes Guesswork Out Of Lateral Flow Testing
- Fastest Ever SARS-CoV-2 Antigen Test Designed for Non-Invasive COVID-19 Testing in Any Setting
- Rapid Antigen Tests Detect Omicron, Delta SARS-CoV-2 Variants
- Health Care Professionals Showed Increased Interest in POC Technologies During Pandemic, Finds Study
- Set Up Reserve Lab Capacity Now for Faster Response to Next Pandemic, Say Researchers
- Blood Test Performed During Initial Infection Predicts Long COVID Risk
- Low-Cost COVID-19 Testing Platform Combines Sensitivity of PCR and Speed of Antigen Tests
- Finger-Prick Blood Test Identifies Immunity to COVID-19
- Quick Test Kit Determines Immunity Against COVID-19 and Its Variants